Drugs / BNP(1-32)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03397966 | Jul 2018 → May 2019 | obesity disorder | VA Office of Research and Development | Terminated | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BNP(1-32) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03397966 ↗ |
| Modality | Peptide | “b-type natriuretic peptide hormone” PMID 38686535 ↗ Apr 2024 |
| Route | Intravenous | “IV infusion of recombinant human BNP(1-32)” NCT03397966 ↗ |